Comparative Analysis of Postoperative Complications of Sentinel Node Identification Using the SentiMag® Method and the Use of a Radiotracer in Patients with Breast Cancer

Andrzej Lorek 1,*, Katarzyna Steinhof-Radwańska 2, Wojciech Zarębski 1, Joanna Lorek 3, Zoran Stojčev 4, Jacek Zych 5, Aleksandra Syrkiewicz 5, Paweł Niemiec 6 and Karol Szyluk 7,8

Abstract: (1) Background: The purpose of the study was a retrospective, comparative assessment of complications of the surgical sentinel node biopsy (SNB) procedure in breast cancer using the radiotracer method and the SentiMag® method on groups of patients after 3.5 years of use. (2) Methods: The material was a group of 345 patients with primary surgical breast cancer who underwent the SNB procedure with the use of a radiotracer in combination with wide local excision (WLE), simple amputation (SA) with SNB and an independent SNB procedure in the period from May 2018 to January 2021 in the Department of Oncological Surgery. Of the patients who were monitored in the Hospital Outpatient Clinic, 300 were enrolled. The analyzed group was compared in terms of the occurrence of the same complications with the group of 303 patients also operated on in our center in the period from January 2014 to September 2017, in which SN identification was performed using the SentiMag® method. (3) Results: The most common complications found were sensation disorders in the arm, which occurred in 16 (14.1%) patients using the radiotracer method, SentiMag® and Karol Szyluk. (4) Conclusions: Sentinel node (SN) identification using the radiotracer method and the SentiMag® method are comparable diagnostic methods in breast cancer, with a low risk of complications.

Keywords: sentinel lymph node biopsy; superparamagnetic particles of iron oxide; SentiMag®; breast cancer; complications

1. Introduction

Surgical sentinel node biopsy (SNB) is currently the standard procedure for assessing regional lymphatic drainage in patients with diagnosed breast cancer without metastases. The procedure allows for a reduction in the number of lymphadenectomies performed, reducing the risk of complications. [1–4] Its use in patients with the clinical feature of N0
allows for the reliable assessment of lymph nodes, with a low risk of recurrence in the event of a negative result [5,6]. The most frequently used reference method is the method with a radiotracer, most often Technetium-99, performed alone or as a dual method in combination with a stain. Postoperative complications related to their use may include allergic reactions, permanent tattooing, limitation of limb mobility and lymphoedema [7,8]. The use of an isotope requires access to a nuclear medicine facility and is associated with a fast half-life, and the use of an isotope is not indifferent to both the patient and the team performing the study. An alternative method is the SentiMag® ferromagnetic method, which uses the Sienna +® colloid, which is a suspension of superparamagnetic iron oxide (SPIO) nanoparticles absorbed by the vessels of lymph nodes. Clinical studies performed in various centers on a large group of patients have shown the equivalence of the SentiMag® method with the standard method with the use of a gamma camera and a radiotracer [9–11]. The SNB procedure is associated with the risk of postoperative complications, the type and frequency of which may differ depending on the SN detection method used [11–13].

The aim of the study was a retrospective, comparative assessment of complications of the SNB procedure in breast cancer using the radiotracer method as a reference and a relatively new SentiMag® method on groups of patients after 3.5 years of use. The numbers of patients in both groups were comparable.

2. Materials and Methods

The study material was a group of 345 patients (median 62.3) with breast cancer, initially treated surgically, who underwent the SNB procedure with the use of a radiotracer. Procedures performed included: wide local excision (WLE), simple amputation (SA) and a stand-alone SNB procedure prior to induction treatment in the period from May 2018 to January 2021 at the Department of Oncological Surgery of the “K. Gibinski” University Clinical Center of the Medical University of Silesia in Katowice. The inclusion criteria for the study included 300 patients who were followed-up at the Hospital Outpatient Cancer Surgery Clinic and whose complications (paresthesia, limb mobility restriction and lymphoedema) were assessed. The longest follow-up period was 37 months, the shortest 5 months (mean 21 months). Before qualifying for the SNB procedure, the patients included in the study were examined and their medical history was taken at the Oncological Surgery Clinic, where the doctor assessed the limb mobility, measured the circumference and collected information about possible sensory disturbances. All patients also had ultrasound of the lymph nodes, and some of them had a fine needle biopsy (FNAB). Patients with unsuspected lymph nodes (c) N0 and no contraindications to the procedure were qualified for SN. The Technetium radiotracer was administered at the Department of Nuclear Medicine of our Center to the tumor area on the day preceding the procedure at approx. 10:00 a.m. Then, after performing lymphoscintigraphy, the patient was admitted to the Surgery Department. The surgical procedure was performed on the following day. The mean time from the administration of the radiotracer to the removal of SN was 18–20 h. Intraoperatively, SN was identified only by gamma camera, and no stain was used. The node with the highest pulse indication was considered SN. In addition, one or two additional nodes were collected, the signal of which were greater than 10% of the former. Each time in the operating protocol, the number of pulses in the identified SN node/nodes was recorded. After the procedure, for the first 2 years, the patients were checked at the Hospital Clinic every 3 months. In addition to the physical examination, ultrasound of the lymph nodes was performed. From the second to the fifth year after the procedure, a check-up was performed every 6 months. The control examination protocol also included the assessment of: (1) sensory disturbances in the form of paresthesia, (2) limb mobility limitation and (3) the presence of lymphoedema.

A reduction in the range of motion by more than 20 degrees compared to the other limb was considered to be a significant limitation of limb mobility. Lymphoedema was determined by measuring the circumference of the limb. A difference between the limbs
of 10% was considered lymphedema: minimal (<20% difference), moderate (difference between 20% and 40%) and severe (>40% difference) [12].

The examination at the clinic was performed by the same team of four surgeons who operated on the patients. All of them have many years of experience in breast surgery. Patients who required armpit lymphadenectomy and/or interrupted the control cycle at the clinic were excluded from the study (31 patients required armpit lymphadenectomy, 14 interrupted the control cycle at the clinic).

The analyzed group was compared in terms of the occurrence of the same complications with a similar (in terms of number of procedures—303) group of patients operated on in our center earlier in the period from January 2014 to September 2017, for whom SN identification was performed using the SentiMag® method. The exclusion criteria were identical to the current study. The operations and control examinations were performed by the same team of surgeons. The recruitment process is shown in Figure 1. Results of this analysis were published in 2019 [13].

Figure 1. Flow diagram demonstrating the recruitment of the study group.

The Statistica 13.1 software (TIBCO Software Inc., Palo Alto, Santa Clara, CA, USA) and a MS Excel (Microsoft Corporation, Redmond, WA, USA) spreadsheet were used for the analysis. The non-parametric Mann–Whitney U test was used to establish the statistical significance of the differences between the incidence of complications and the number of removed lymph nodes. The significance of the remaining differences indicated in the multi-way tables was verified using the $\chi^2$ independence test. The level of statistical significance was adopted at the $\alpha$ level equal to 5%. Hence, $p < 0.05$ was adopted as the limit value of the probability of the test characteristics for which the differences were considered statistically significant.

3. Results

A total of 300 patients with SNB procedure were included in the study, with an age range of 29–87 years (mean 63 years). A total of 191 SNB procedures with wide local excision (WLE), 95 SNB procedures combined with simple amputation of the mammary gland (SA) and 14 standalone SNB procedures were performed prior to systemic treatment.
In total, 864 lymph nodes were removed in all procedures. The SN identification rate in all procedures was 100%.

The mean of SN removed in one procedure with a radiotracer in the whole group was 2.9 (SentiMag®-2.9), with the standalone SNB procedure 3.2 (SentiMag®-1.8), with wide local excision (WLE) with SNB 2.4 (SentiMag®-2.5) and in simple amputation with SNB-3.2 (SentiMag®-3.6). The median follow-up was 26 months for WLE with SNB ((SentiMag®), 25 months, 27 months for simple amputation with SNB (SentiMag®-26 months) and 11 months for SNB (SentiMag®-9 months) (Table 1).

| Complication               | Radiotracer | SentiMag® |
|----------------------------|-------------|-----------|
| WLE + SNB                  | SA + SNB    | SNB       |
| Paresthesia, n (%)         | 5 (2.62)    | 11 (11.58)| 0 (0.00)  |
| Restricted upper limb mobility, ROM n (%) | 5 (2.62) | 7 (7.37) | 0 (0.00)  |
| Edema, n (%)               | 4 (2.09)    | 9 (9.47)  | 0 (0.00)  |

The occurrence of paresthesia, restricted mobility and lymphedema was analyzed depending on the number of lymph nodes removed. A significant dependence of these complications on the number of lymph nodes removed in the SNB procedure in both methods was demonstrated (Table 3).

Table 1. General data.

Table 2. Complications in both methods.

Table 3. Statistical significance (P) of differences between number of removed nodes depending on the occurrence of a complication and the kind on procedure in both methods (radiotracer and SentiMag).
of paresthesia and lymphoedema in SA with SNB compared to WLE with SNB in both methods. In the case of limb mobility restriction, no significant differences were observed depending on the type of surgery in both methods (Table 4).

Table 4. The results of the chi independence test between the difference in the frequency of treatments (SA vs. WLE) depending on the complication occurrence for both methods (Radiotracer and SentiMag).

| Complication                | Radiotracer       | SentiMag®          |
|-----------------------------|-------------------|--------------------|
| Paresthesia                 | $\chi^2 (1; N = 286) = 9646; p = 0.002$ | $\chi^2 (1; N = 298) = 8304; p = 0.004$ |
| Restricted upper limb       | $\chi^2 (1; N = 286) = 3562; p = 0.059$ | $\chi^2 (1; N = 298) = 3816; p = 0.051$ |
| mobility, ROM               | $\chi^2 (1; N = 286) = 7963; p = 0.005$ | $\chi^2 (1; N = 298) = 707; p = 0.008$ |
| Edema                       |                   |                    |

The comparative analysis of the analyzed complications in the identification of SN did not show any significant differences in both methods (Table 5).

Table 5. Statistical significance of differences in the number of complications between the methods with the radiotracer (n = 300) and SentiMag® (n = 303).

| Complication                | $p$ Value | $\chi^2$ Test Result |
|-----------------------------|-----------|----------------------|
| Paresthesia                 | 0.4231    | 0.642                |
| Restricted upper limb       | 0.4905    | 0.476                |
| mobility, ROM               | 0.3721    | 0.797                |
| Edema                       |           |                      |

In the SentiMag® method, skin discoloration was observed after the application of the Sienna +® marker in the form of a brown-gray tattoo. The SentiMag® method failed to detect the SN in two patients (0.5%) [13]. In the radiotracer method, SN was identified in all patients. In 34 patients (9.2%) in the SentiMag® method and in 31 patients (8.9%) in the radiotracer method, histopathological examination of the material resulting from the SNB procedure revealed the presence of macrometastases in sentinel nodes, with infiltration of the capsule or the presence of neoplastic cells in the perinodular adipose tissue. These cases required an axillary lymphadenectomy and were excluded from the analysis.

4. Discussion

The sentinel node biopsy (SNB) procedure is the primary diagnostic method in the treatment of breast cancer for the evaluation of regional lymph node involvement on the path of lymphatic drainage from the tumor area. The result of this test makes it possible to decide on the treatment method. The method using a Technetium radiotracer (99 mTc) alone or in the double dye method is still considered the “gold standard” of node identification during the SNB procedure. The comparable effectiveness in this procedure has also been demonstrated using the SentiMag® method, introduced a few years ago [9,14]. Complications may occur in both the Sienna +® and radionuclide methods, but their frequency is much lower than in the case of axillary lymph node dissection (ALND).

A significant postoperative complication associated with SNB is lymphoedema, which occurs in 5–6% of patients subjected to this procedure. It may result in a reduction in the range of mobility of the upper limb, stiffness, numbness, as well as pain, reduction of self-esteem, secondary neoplasms and a tendency to withdraw from social life [12,15].

In our study, minimal grade lymphoedema occurred in 13 out of 300 patients (4.3%) with the use of the radiotracer, and in 9 out of 303 patients (2.9%) with the SentiMag® method (2.9%). Based on the collected data, there was no statistically significant difference in the incidence of lymphoedema between SentiMag® and the radiotracer method ($p=0.3721$). In our study, the application of the SNB procedure with the use of a radiotracer was associated with a low incidence of lymphoedema: WLE with SNB (9.47%), SA with SNB (2.09%) and with standalone SNB (0%). Similarly, in the method using SentiMag® for WLE
with SNB (1.05%), for SA with SNB (6.54%) and standalone SNB (0%). In both methods, we demonstrated a statistically significant more frequent occurrence of lymphoedema with an increasing number of lymph nodes removed by simple amputation (SA) combined with SNB ($p = 0.0000$ and $p = 0.0426$). In cases of wide local excision (WLE) in combination with SNB, no significant differences were observed in both methods ($p = 0.0785$ and $p = 0.1712$). These differences probably result from the extent of the procedure. In simple amputation, an additional number of mute lymph nodes can be diagnostically removed along with Spence’s tail, which is clearly visible in the average number of removed nodes in both procedures (WLE with SNB—2.4 v. SA with SNB—3.2).

According to Aase Sagen et al. [16], the incidence of lymphedema 2.5 years after the surgery was 17% for the ALND procedure compared to 3% for the SNB procedure. In a large randomized clinical trial of NSABP B-32 [17], women with invasive breast cancer under-went SNB followed by ALND (group 1) or SNB followed by ALND only in the presence of sentinel nodal metastases (group 2). The 8-year overall and disease-free survival in both groups was found to be similar; the overall survival was 91.8% in Group 1 and 90.3% in Group 2, while the disease-free survival was 82.4% in Group 1 and 81.5% in Group 2. The authors concluded that with comparable survival in both of these treatments, it seemed reasonable to strive to remove as few lymph nodes as possible, and therefore routinely use the SNB procedure and possibly subsequent dissection of affected nodes, because this approach reduces the risk of lymphoedema in patients and, consequently, increases quality of life without affecting survival.

Another complication observed in our study was the presence of limitations in the mobility of the upper limb on the side of lymph node removal. They occurred after the use of the radiotracer in 12 out of 300 patients (4%) and in the SentiMag® method in 9 out of 303 patients (2.9%). Again, a statistically significant correlation was demonstrated be-tween the frequency of mobility limitations and the number of surgically removed lymph nodes in both methods: radiotracer (WLE + SNB $p<0.0002$ and SA + SNB $p<0.0000$) and Sen-tiMag® (WLE + SNB $p=0.0307$ and SA + SNB $p=0.0426$).

Paresthesia in the upper limb on the side of the procedure occurred with the use of a radiotracer in 16 out of 300 patients (5.3%) and with the use of superparamagnetics in 12 out of 303 patients (3.9%). In our study, paresthesia was significantly more frequent in the case of the SA + SNB procedure compared to the WLE + SNB procedure in both methods (radiotracer: $p=0.0043$; SentiMag®: $p=0.0040$). Despite the fact that in our study, no complications occurred for both methods after standalone SNB, other authors emphasized that despite the low invasiveness of this procedure, it may be followed by paresthesia, lymphoedema and limb mobility impairment [18]. As a result of applying the SentiMag® method, a brown-gray skin discoloration was observed at the place where the Sienna+® marker was administered. The discoloration receded completely after 1.5 year [13].

In the study by Ghilli M. et al. [19], the presence of tattoos was found in 47.3% of the studied group. Tattoo reduction occurred in 70.4% of patients and complete disappearance in 20.1% after an average of 5.9 months of follow-up in a group of 150 patients. In one (1.4%) patient the discoloration was enlarged, and in five (7.1%) patients the discoloration was not visibly reduced. On the other hand, in The Nordic SentiMag Trial [20], depigmentation occurred in 35.5% of patients and remained slightly paler and smaller after one year in 21% of patients and in 8.6% of patients after 15 months. In our ward, the SPIO injection was performed deep under the areola of the nipple, to a depth of 1–2 cm, resulting in a lower incidence of discoloration, which is also confirmed by reports by other authors [19,20]. The possibility of temporary discoloration should be the subject of information for patients undergoing this procedure.

In both methods, we demonstrated a similar effectiveness in terms of SN identification as well as a comparable risk of complications. Taking this into account and considering the fewer logistical difficulties associated with the use of the SentiMag® method, the popularization of this method seems to be a direction worth considering in the diagnosis of regional lymph nodes in breast cancer. According to Ean-Louis Houpeau et al. [9], the
use of superferromagnetism may turn out to be a good direction of development due to the possibility of the availability of nuclear reactors in Europe being limited, in which the radionuclide is produced. Another advantage of SPIO is the lack of a requirement for a nuclear medicine facility on the premises of a medical institution and absence of the transport difficulties typically associated with radioactive elements. Additionally, its use reduces the risk associated with exposure to ionizing radiation, both for staff and patients. Another relevant factor for both methods is their cost. The SentiMag is slightly more expensive than the standard radiomarker method.

The study is limited by the size of the sample as well as the fact that both the patient’s body mass index (BMI) and comorbidities were not taken into consideration.

5. Conclusions
SN identification using the radiotracer method and the SentiMag® method are comparable diagnostic methods in breast cancer, with a low risk of complications.

Author Contributions: Conceptualization, A.L. and K.S.-R.; methodology, A.L., K.S.-R., Z.S. and W.Z.; software, P.N., K.S. and A.L.; validation, A.L. and K.S.-R.; formal analysis, A.L., K.S. and K.S.-R.; investigation, A.L., W.Z. and K.S.-R., writing—original draft preparation, A.L., K.S.-R., J.Z., A.S. and J.L.; writing—review and editing, A.L., K.S.-R., P.N. and K.S.; design of the manuscript, P.N., K.S.-R. and J.L.; supervision, K.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki. Due to the retrospective nature of this study, the local ethics committee of the Medical University of Silesia repealed the requirement of informed consent (decision number CBN/022/KB1/88/21).

Informed Consent Statement: Due to the retrospective nature of this study, the local ethics committee of the Medical University of Silesia repealed the requirement of informed consent.

Data Availability Statement: Data is available upon special request.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Veronesi, U.; Paganelli, G.; Viale, G.; Luini, A.; Zurrida, S.; Galimberti, V.; Intra, M.; Veronesi, P.; Robertson, C.; Maisonneuve, P.; et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. *N. Engl. J. Med.* 2003, 349, 546–553. [CrossRef] [PubMed]
2. Lyman, G.H.; Temin, S.; Edge, S.B.; Newman, L.A.; Turner, R.R.; Weaver, D.L.; Benson, A.B., 3rd; Bosserman, L.D.; Burstein, H.J.; Cody, H., 3rd; et al. American Society of Clinical Oncology Clinical Practice. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. *J. Clin. Oncol.* 2014, 32, 1365–1383. [CrossRef] [PubMed]
3. Apple, S.K. Sentinel Lymph Node in Breast Cancer: Review Article from a Pathologist’s Point of View. *J. Pathol. Transl. Med.* 2016, 50, 83–95. [CrossRef] [PubMed]
4. Gherghe, M.; Bordea, C.; Bliadaru, A. Sentinel lymph node biopsy (SLNB) vs. axillary lymph node dissection (ALND) in the current surgical treatment of early stage breast cancer. *J. Med. Life* 2015, 8, 176–180. [PubMed]
5. Giuliano, A.E.; Hunt, K.K.; Ballman, K.V.; Beitsch, P.D.; Whitworth, P.W.; Blumencranz, P.W.; Leitch, A.M.; Saha, S.; McCall, L.M.; Morrow, M. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. *JAMA* 2011, 305, 569–575. [CrossRef] [PubMed]
6. Reedy, S.; Patani, N.; Anderson, A.; Burgoyne, G.; Osman, H.; Mokbel, K. Oncological outcome and patient satisfaction with skin-sparing mastectomy and immediate breast reconstruction: A prospective observational study. *BMC Cancer* 2010, 10, 171. [CrossRef] [PubMed]
7. Wang, Z.; Wu, L.C.; Chen, J.Q. Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: A meta-analysis. *Breast Cancer Res. Treat.* 2011, 129, 675–689. [CrossRef] [PubMed]
8. Ashikaga, T.; Krag, D.N.; Land, S.R.; Julian, T.B.; Anderson, S.J.; Brown, A.M.; Skelly, J.M.; Harlow, S.P.; Weaver, D.L.; Mamounas, E.P.; et al. National Surgical Adjuvant Breast, Bowel Project. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. *J. Surg. Oncol.* 2010, 102, 111–118. [CrossRef] [PubMed]
9. Houpeau, J.L.; Chauvet, M.P.; Guillemin, F.; Bendavid-Athias, C.; Charitansky, H.; Kramar, A.; Giard, S. Sentinel lymph node identification using superparamagnetic iron oxide particles versus radioisotope: The French Sentimag feasibility trial. *J. Surg. Oncol.* 2016, 113, 501–507. [CrossRef] [PubMed]

10. Coufal, O.; Fait, V.; Lžiˇ caˇ rová, E.; Chrenko, V.; Žaloudík, J. SentiMag—The magnetic detection system of sentinel lymph nodes in breast cancer. *Rozhl. Chir.* 2015, 94, 283–288. [PubMed]

11. Douek, M.; Klaase, J.; Monypenny, I.; Kothari, A.; Zechmeister, K.; Brown, D.; Wyld, L.; Drew, P.; Garmo, H.; Agbaje, O.; et al. SentiMAG Trialists Group. Sentinel node biopsy using a magnetic tracer versus standard technique: The SentiMAG Multicentre Trial. *Ann. Surg. Oncol.* 2014, 21, 1237–1245. [CrossRef] [PubMed]

12. Velanovich, V.; Szymanski, W. Quality of life of breast cancer patients with lymphedema. *Am. J. Surg.* 1999, 177, 184–187. [CrossRef]

13. Lorek, A.; Stojˇ cev, Z.; Zar˛ ebski, W.; Kowalczyk, M.; Szyłuk, K. Analysis of Postoperative Complications After 303 Sentinel Lymph Node Identification Procedures Using the SentiMag® Method in Breast Cancer Patients. *Med. Sci. Monit.* 2019, 25, 3154–3160. [CrossRef] [PubMed]

14. Thill, M.; Kurylcio, A.; Welter, R.; van Haasteren, V.; Grosse, B.; Berclaz, G.; Polkowski, W.; Hauser, N. The Central-European SentiMag study: Sentinel lymph node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotope. *Breast* 2014, 23, 175–179. [CrossRef] [PubMed]

15. Taghian, N.R.; Miller, C.L.; Jammallo, L.S.; O’Toole, J.; Skolny, M.N. Lymphedema following breast cancer treatment and impact on quality of life: A review. *Crit. Rev. Oncol. Hematol.* 2014, 92, 227–234. [CrossRef] [PubMed]

16. Sagen, A.; Kaaresen, R.; Sandvik, L.; Thune, I.; Risberg, M.A. Upper limb physical function and adverse effects after breast cancer surgery: A prospective 2.5-year follow-up study and preoperative measures. *Arch. Phys. Med. Rehabil.* 2014, 95, 875–881. [CrossRef] [PubMed]

17. Krag, D.N.; Anderson, S.J.; Julian, T.B.; Brown, A.M.; Harlow, S.P.; Costantino, J.P.; Ashikaga, T.; Weaver, D.L.; Mamounas, E.P.; Jalovec, L.M.; et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. *Lancet Oncol.* 2010, 11, 927–933. [CrossRef]

18. Kootstra, J.J.; Hoekstra-Webers, J.E.; Rietman, J.S.; de Vries, J.; Baas, P.C.; Geertzen, J.H.; Hoekstra, H.J. A longitudinal comparison of arm morbidity in stage I-II breast cancer patients treated with sentinel lymph node biopsy, sentinel lymph node biopsy followed by completion lymph node dissection, or axillary lymph node dissection. *Ann. Surg. Oncol.* 2010, 17, 2384–2394. [CrossRef] [PubMed]

19. Ghilli, M.; Carretta, E.; Di Filippo, F.; Battaglia, C.; Fustaino, L.; Galanou, I.; Di Filippo, S.; Rucci, P.; Fantini, M.P.; Roncella, M. The superparamagnetic iron oxide tracer: A valid alternative in sentinel node biopsy for breast cancer treatment. *Eur. J. Cancer Care* 2017, 26, e12385. [CrossRef] [PubMed]

20. Karakatsanis, A.; Christiansen, P.M.; Fischer, L.; Hedin, C.; Pistioli, L.; Sund, M.; Rasmussen, N.R.; Jørnsågard, H.; Tegnelius, D.; Eriksson, S.; et al. The Nordic SentiMag trial: A comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc(99) and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies. *Breast Cancer Res. Treat.* 2016, 157, 281–294. [CrossRef] [PubMed]